Area of research
Endocrinology, Diabetes and Metabolism · Orthopedics and Sports Medicine
Research interest
Research interests include Diabetes Management and Research, Diabetes Treatment and Management, Bone health and osteoporosis research, and Metabolism, Diabetes, and Cancer.
Causes of difficulties with adequate levothyroxine substitution - an immunoendocrine perspective.
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2022.
Longitudinal strain bull’s eye plot patterns in young women with type 1 diabetes – association of regional cardiac systolic function with thyroid autoimmunity and iron status
[Is thyroid autoimmunity associated with subclinical atherosclerosis in young women with type 1 diabetes mellitus?]
[Association of antithyroid peroxidase antibodies with cardiac function in euthyroid women with type 1 diabetes mellitus - assessment with two-dimensional speckle‑tracking echocardiography].
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
Amputations of Lower Limb in Subjects with Diabetes Mellitus: Reasons and 30-Day Mortality.
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Predictors of Rehospitalization and Mortality in Diabetes-Related Hospital Admissions.
Prevalence and socioeconomic predictors of diagnosed and undiagnosed diabetes in oldest-old and younger Caucasian seniors: results from the PolSenior study.
Incidence of non-hereditary amyloidosis in Poland
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Sensitivity and specificity of prediction models based on gustatory disorders in diagnosing COVID-19 patients: a case-control study
Influence of Chronic Periodontitis on the Long-Term Mortality and Cardiovascular Events in Kidney Transplant Recipients.
Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes-Cohort Studies.
Correction to: Impact of air pollution on hospital admissions with a focus on respiratory diseases: a time-series multi-city analysis.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Impact of air pollution on hospital admissions with a focus on respiratory diseases: a time-series multi-city analysis.
Distribution of the Highest Plantar Pressure Regions in Patients with Diabetes and Its Association with Peripheral Neuropathy, Gender, Age, and BMI: One Centre Study.
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial
Étude LEADER - liraglutide et événements cardiovasculaires : analyse complémentaire chez les sujets âgés ≥ 75 ans
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)
LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: <scp>IMAGINE</scp> 3